Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Payables (2022 - 2026)

HeartSciences (HSCS) has disclosed Payables for 4 consecutive years, with $817390.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 69.08% year-over-year to $817390.0, compared with a TTM value of $817390.0 through Oct 2025, down 69.08%, and an annual FY2025 reading of $2.9 million, up 202.67% over the prior year.
  • Payables was $817390.0 for Q4 2025 at HeartSciences, down from $1.8 million in the prior quarter.
  • Across five years, Payables topped out at $2.9 million in Q1 2025 and bottomed at $396506.0 in Q3 2024.
  • Average Payables over 4 years is $1.6 million, with a median of $1.2 million recorded in 2023.
  • Peak annual rise in Payables hit 360.11% in 2025, while the deepest fall reached 69.08% in 2025.
  • Year by year, Payables stood at $1.9 million in 2022, then soared by 30.13% to $2.5 million in 2023, then rose by 5.52% to $2.6 million in 2024, then plummeted by 69.08% to $817390.0 in 2025.
  • Business Quant data shows Payables for HSCS at $817390.0 in Q4 2025, $1.8 million in Q3 2025, and $2.9 million in Q2 2025.